FREMONT, Calif., April 24 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc.
(PDL) (Nasdaq: PDLI) today announced that the company's Board of Directors
elected Bradford S. Goodwin as a member of its Board of Directors.
"Brad's 25 years of biotechnology industry and financial experience
will be valuable as we seek to advance our product pipeline and expand our
commercial operations in order to sustain long-term growth and build
shareholder value," said Max Link, Ph.D., PDL BioPharma's Chairman of the
Board of Directors.
Goodwin is Chief Executive Officer of Novacea, a privately-held
biopharmaceutical company focused on in-licensing, developing and
commercializing novel therapies for cancer. Under his leadership, Novacea
has in-licensed three clinical-stage oncology product candidates, including
DN-101, which is currently in a pivotal Phase 3 clinical study for the
treatment of advanced prostate cancer. He has also led Novacea in raising
over $100 million.
Prior to Novacea, Goodwin was President, Chief Operating Officer and
Founder of Collabra Pharma, a company focused on pharmaceutical product
licensing and development. Before starting Collabra, he held various senior
executive positions with Genentech, Inc., including Vice President of
Finance, and was responsible for treasury, purchasing, risk management,
real estate, controllership, tax and long-range planning.
Goodwin has served on expert advisory committees of the American
Institute of Certified Public Accountants and the Financial Accounting
Standards Board, and holds a B.S. in business administration from the
University of California, Berkeley.
Forward Looking Statements
The information in this press release should be considered accurate
only as of the date of the release. PDL has no intention of updating and
specifically disclaims any duty to update the information in this press
release for any reason, except as required by law, even as new information
becomes available or other events occur in the future. This press release
may contain "forward-looking statements" that are based on current
expectations and assumptions that are subject to risks and uncertainties.
PDL's actual results may differ materially from those in the
forward-looking statements because of various factors, risks and
uncertainties. For further information regarding factors, risks and
uncertainties that may cause such differences, please refer to PDL's Annual
Report on Form 10-K for the year ended December 31, 2005, including the
"Risk Factors" section of that report, and other filings PDL has made with
the Securities and Exchange Commission, copies of which may be obtained at
the "Investors" section on PDL's website at http://www.pdl.com. All
forward-looking statements in this press release are qualified in their
entirety by this cautionary statement.
About PDL BioPharma
PDL BioPharma, Inc. is a biopharmaceutical company focused on
discovering, developing and commercializing innovative therapies for severe
or life- threatening illnesses. The company currently markets and sells a
portfolio of leading products in the acute-care hospital setting in the
United States and Canada and generates royalties through licensing
agreements with top-tier biotechnology and pharmaceutical companies based
on its pioneering antibody humanization technology. Currently, PDL
BioPharma's diverse late-stage product pipeline includes six
investigational compounds in Phase 2 or Phase 3 clinical development for
hepatorenal syndrome, autoimmune and inflammatory diseases, cardiovascular
disorders and cancer. Further information on PDL BioPharma is available at
http://www.pdl.com.
PDL BioPharma and the PDL BioPharma logo are considered trademarks of
PDL BioPharma, Inc.
SOURCE PDL BioPharma, Inc.
 back to top
Related links:
http://www.pdl.com
CONTACT:
Ami Knoefler, Corporate and Investor
Relations, +1-510-284-8851, ami.knoefler@pdl.com, or Jim Goff,
Investor Relations, +1-510-574-1421, james.goff@pdl.com, both of
PDL BioPharma, Inc.
|
